Biocon launches insulin glargine in India
This article was originally published in Scrip
Executive Summary
Biocon, an Indian biotechnology company, has launched its long-acting human insulin analogue, glargine (marketed as Basalog), a version of Sanofi Aventis' Lantus, on the domestic market. Basalog is available in 10ml and 3ml vials. Long-acting insulin analogues such as glargine are believed to facilitate better metabolic control and also slow the progression of the disease with fewer advanced diabetic complications such as retinopathy, neuropathy, nephropathy and cardiac complications like hypertension, myocardial infarction or stroke.